CL3-78989-002

• Research type

  Research Study

• Full title

  A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis.

• IRAS ID

  111647

• Contact name

  Miles Stanford

• Sponsor organisation

  Servier R&D

• Eudract number

  2012-001125-27

• ISRCTN Number

  xx

• Research summary

  This is an exploratory study aiming to assess both the efficacy and safety of Gevokizumab in patients with Behҫet’s disease uveitis (an inflammatory eye disorder). Gevokizumab will be compared to placebo when used in addition to the standard treatment prescribed for Behҫet’s disease uveitis. The study will last for up to 56 months.

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  12/LO/1650

• Date of REC Opinion

  15 Jan 2013

• REC opinion

  Further Information Favourable Opinion